Search

Your search keyword '"Sijbrands Ejg."' showing total 92 results

Search Constraints

Start Over You searched for: Author "Sijbrands Ejg." Remove constraint Author: "Sijbrands Ejg."
92 results on '"Sijbrands Ejg."'

Search Results

5. Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohort

6. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

7. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

8. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

9. Interactions of Dietary Whole-Grain Intake With Fasting Glucose– and Insulin-Related Genetic Loci in Individuals of European Descent

11. Pleiotropy among common genetic loci identified for cardiometabolic disorders and C-reactive protein

12. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure

13. Erratum: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (Nature Genetics (2010) 42 (105-116))

14. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (vol 42, pg 105, 2010)

15. Plasma phospholipid transfer protein activity is decreased in type 2diabetes during treatment with atorvastatin - A role for apolipoprotein E?

16. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

17. Biological, clinical and population relevance of 95 loci for blood lipids

18. Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals

21. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study.

22. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?

24. Poster session Thursday 12 December - PM: 12/12/2013, 14:00-18:00 * Location: Poster area

25. Poster session Friday 13 December - AM: 13/12/2013, 08:30-12:30 * Location: Poster area

27. Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach

29. The effects of APOE4 and familial Alzheimer's disease mutations on free fatty acid profiles in mouse brain are age- and sex-dependent.

30. Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model.

31. Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model.

32. Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.

33. Defining type 2 diabetes polygenic risk scores through colocalization and network-based clustering of metabolic trait genetic associations.

34. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study.

35. Identifying lipid traces of atherogenic mechanisms in human carotid plaque.

36. Apolipoprotein-CIII O -Glycosylation, a Link between GALNT2 and Plasma Lipids.

37. Heart Rate Variability and Incident Type 2 Diabetes in General Population.

38. Lipoprotein(a) is associated with a larger systemic burden of arterial calcification.

39. Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non- APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline.

40. Associations of baseline glycemic status and its transitions with cognitive and physical functioning decline.

41. Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification.

42. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.

43. Cross-Laboratory Standardization of Preclinical Lipidomics Using Differential Mobility Spectrometry and Multiple Reaction Monitoring.

44. The effect of monomeric and oligomeric FLAVAnols in patients with type 2 diabetes and microalbuminuria (FLAVA-trial): A double-blind randomized controlled trial.

45. Effects of Sex, Age, and Apolipoprotein E Genotype on Brain Ceramides and Sphingosine-1-Phosphate in Alzheimer's Disease and Control Mice.

46. Genetic susceptibility, obesity and lifetime risk of type 2 diabetes: The ARIC study and Rotterdam Study.

47. Plasma protein N- glycosylation is associated with cardiovascular disease, nephropathy, and retinopathy in type 2 diabetes.

48. HDL associates with insulin resistance and beta-cell dysfunction in South Asian families at risk of type 2 diabetes.

49. Lipoprotein(a) is robustly associated with aortic valve calcium.

50. Breakfast partly restores the anti-inflammatory function of high-density lipoproteins from patients with type 2 diabetes mellitus.

Catalog

Books, media, physical & digital resources